In recent years, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Adult Cancer Pain have undergone substantial revisions focusing on the appropriate and safe prescription of opioid analgesics, optimization of nonopioid analgesics and adjuvant medications, and integration of nonpharmacologic methods of cancer pain management. This selection highlights some of these changes, covering topics on management of adult cancer pain including pharmacologic interventions, nonpharmacologic interventions, and treatment of specific cancer pain syndromes. The complete version of the NCCN Guidelines for Adult Cancer Pain addresses additional aspects of this topic, including pathophysiologic classification of cancer pain syndromes, comprehensive pain assessment, management of pain crisis, ongoing care for cancer pain, pain in cancer survivors, and specialty consultations.
Individual Disclosures for the NCCN Adult Cancer Pain Panel
van den Beuken-van EverdingenMH, de RijkeJM, KesselsAG, et al.. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol2007;18:1437–1449.
van den Beuken-van EverdingenMH, de RijkeJM, KesselsAG, . Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol 2007;18:1437–1449.10.1093/annonc/mdm056)| false
Te BoveldtN, Vernooij-DassenM, BurgerN, et al.. Pain and its interference with daily activities in medical oncology outpatients. Pain Physician2013;16:379–389.
Te BoveldtN, Vernooij-DassenM, BurgerN, . Pain and its interference with daily activities in medical oncology outpatients. Pain Physician 2013;16:379–389.)| false
TemelJS, GreerJA, MuzikanskyA, . Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010;363:733–742.10.1056/NEJMoa100067820818875)| false
ZimmermannC, SwamiN, KrzyzanowskaM, et al.. Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial. Lancet2014;383:1721–1730.
ZimmermannC, SwamiN, KrzyzanowskaM, . Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial. Lancet 2014;383:1721–1730.10.1016/S0140-6736(13)62416-2)| false
GrudzenCR, RichardsonLD, JohnsonPN, et al.. Emergency department-initiated palliative care in advanced cancer: a randomized clinical trial. JAMA Oncol2016;2:591–598.
BakitasMA, TostesonTD, LiZ, et al.. Early versus delayed initiation of concurrent palliative oncology care: patient outcomes in the ENABLE III randomized controlled trial. J Clin Oncol2015;33:1438–1445.
BakitasMA, TostesonTD, LiZ, . Early versus delayed initiation of concurrent palliative oncology care: patient outcomes in the ENABLE III randomized controlled trial. J Clin Oncol 2015;33:1438–1445.10.1200/JCO.2014.58.636225800768)| false
BakitasM, LyonsKD, HegelMT, et al.. Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: the Project ENABLE II randomized controlled trial. JAMA2009;302:741–749.
BakitasM, LyonsKD, HegelMT, . Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: the Project ENABLE II randomized controlled trial. JAMA 2009;302:741–749.10.1001/jama.2009.1198)| false
GrecoMT, RobertoA, CorliO, et al.. Quality of cancer pain management: an update of a systematic review of undertreatment of patients with cancer. J Clin Oncol2014;32:4149–4154.
GrecoMT, RobertoA, CorliO, . Quality of cancer pain management: an update of a systematic review of undertreatment of patients with cancer. J Clin Oncol 2014;32:4149–4154.2540322210.1200/JCO.2014.56.0383)| false
PassikSD, WeinrebHJ. Managing chronic nonmalignant pain: overcoming obstacles to the use of opioids. Adv Ther 2000;17:70–83.10.1007/BF0285484011010058)| false
CleelandCS, GoninR, HatfieldAK, . Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 1994;330:592–596.750809210.1056/NEJM199403033300902)| false
StjernswärdJ, ColleauSM, VentafriddaV. The World Health Organization Cancer Pain and Palliative Care Program. Past, present, and future. J Pain Symptom Manage1996;12:65–72.
StjernswärdJ, ColleauSM, VentafriddaV. The World Health Organization Cancer Pain and Palliative Care Program. Past, present, and future. J Pain Symptom Manage 1996;12:65–72.10.1016/0885-3924(96)00109-18754982)| false
SyrjalaKL, AbramsJR, PolissarNL, et al.. Patient training in cancer pain management using integrated print and video materials: a multisite randomized controlled trial. Pain2008;135:175–186.
SyrjalaKL, AbramsJR, PolissarNL, . Patient training in cancer pain management using integrated print and video materials: a multisite randomized controlled trial. Pain 2008;135:175–186.1809373810.1016/j.pain.2007.10.026)| false
MercadanteSL, BerchovichM, CasuccioA, et al.. A prospective randomized study of corticosteroids as adjuvant drugs to opioids in advanced cancer patients. Am J Hosp Palliat Care2007;24:13–19.
MercadanteSL, BerchovichM, CasuccioA, . A prospective randomized study of corticosteroids as adjuvant drugs to opioids in advanced cancer patients. Am J Hosp Palliat Care 2007;24:13–19.10.1177/104990910629543117347500)| false
StocklerM, VardyJ, PillaiA, et al.. Acetaminophen (paracetamol) improves pain and well-being in people with advanced cancer already receiving a strong opioid regimen: a randomized, double-blind, placebo-controlled cross-over trial. J Clin Oncol2004;22:3389–3394.
StocklerM, VardyJ, PillaiA, . Acetaminophen (paracetamol) improves pain and well-being in people with advanced cancer already receiving a strong opioid regimen: a randomized, double-blind, placebo-controlled cross-over trial. J Clin Oncol 2004;22:3389–3394.10.1200/JCO.2004.09.122)| false
American Geriatrics Society Panel on Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc2009;57:1331–1346.
American Geriatrics Society Panel on Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc 2009;57:1331–1346.19573219)| false
IsraelFJ, ParkerG, CharlesM, et al.. Lack of benefit from paracetamol (acetaminophen) for palliative cancer patients requiring high-dose strong opioids: a randomized, double-blind, placebo-controlled, crossover trial. J Pain Symptom Manage2010;39:548–554.
U.S. Food and Drug Administration. FDA Drug Safety Communication: Prescription acetaminophen products to be limited to 325 mg per dosage unit; boxed warning will highlight potential for severe liver failure. 2011. Available at: http://www.fda.gov/drugs/drugsafety/ucm239821.htm. Accessed March 7, 2019.
TielemansMM, EikendalT, JansenJB, et al.. Identification of NSAID users at risk for gastrointestinal complications: a systematic review of current guidelines and consensus agreements. Drug Saf2010;33:443–453.
TielemansMM, EikendalT, JansenJB, . Identification of NSAID users at risk for gastrointestinal complications: a systematic review of current guidelines and consensus agreements. Drug Saf 2010;33:443–453.10.2165/11534590-000000000-0000020486727)| false
LaineL, CurtisSP, CryerB, et al.. Risk factors for NSAID-associated upper GI clinical events in a long-term prospective study of 34 701 arthritis patients. Aliment Pharmacol Ther2010;32:1240–1248.
LaineL, CurtisSP, CryerB, . Risk factors for NSAID-associated upper GI clinical events in a long-term prospective study of 34 701 arthritis patients. Aliment Pharmacol Ther 2010;32:1240–1248.10.1111/j.1365-2036.2010.04465.x)| false
U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes. 2015. Available at: https://www.fda.gov/drugs/drugsafety/ucm451800. Accessed April 12, 2019.
32.
BallyM, DendukuriN, RichB, et al.. Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data. BMJ2017;357:j1909.
BallyM, DendukuriN, RichB, . Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data. BMJ 2017;357:j1909.2848743510.1136/bmj.j1909)| false
JongenJL, HuijsmanML, JessurunJ, et al.. The evidence for pharmacologic treatment of neuropathic cancer pain: beneficial and adverse effects. J Pain Symptom Manage2013;46:581–590 e581.
JongenJL, HuijsmanML, JessurunJ, . The evidence for pharmacologic treatment of neuropathic cancer pain: beneficial and adverse effects. J Pain Symptom Manage 2013;46:581–590 e581.10.1016/j.jpainsymman.2012.10.230)| false
JinY, DestaZ, StearnsV, et al.. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst2005;97:30–39.
JinY, DestaZ, StearnsV, . CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005;97:30–39.1563237810.1093/jnci/dji005)| false
HaqueR, ShiJ, SchottingerJE, et al.. Tamoxifen and antidepressant drug interaction in a cohort of 16,887 breast cancer survivors. J Natl Cancer Inst2016;108:(3)
HaqueR, ShiJ, SchottingerJE, . Tamoxifen and antidepressant drug interaction in a cohort of 16,887 breast cancer survivors. J Natl Cancer Inst 2016;108:(3)10.1093/jnci/djv337)| false
AzoulayL, Dell’AnielloS, HuiartL, et al.. Concurrent use of tamoxifen with CYP2D6 inhibitors and the risk of breast cancer recurrence. Breast Cancer Res Treat2011;126:695–703.
AzoulayL, Dell’AnielloS, HuiartL, . Concurrent use of tamoxifen with CYP2D6 inhibitors and the risk of breast cancer recurrence. Breast Cancer Res Treat 2011;126:695–703.2084818610.1007/s10549-010-1162-y)| false
Johannessen LandmarkC. Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs2008;22:27–47.
Johannessen LandmarkC. Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs 2008;22:27–47.10.2165/00023210-200822010-00003)| false
BaronR, BrunnmüllerU, BrasserM, et al.. Efficacy and safety of pregabalin in patients with diabetic peripheral neuropathy or postherpetic neuralgia: Open-label, non-comparative, flexible-dose study. Eur J Pain2008;12:850–858.
ChenDL, LiYH, WangZJ, et al.. The research on long-term clinical effects and patients’ satisfaction of gabapentin combined with oxycontin in treatment of severe cancer pain. Medicine (Baltimore)2016;95:e5144.
ChenDL, LiYH, WangZJ, . The research on long-term clinical effects and patients’ satisfaction of gabapentin combined with oxycontin in treatment of severe cancer pain. Medicine (Baltimore) 2016;95:e5144.10.1097/MD.000000000000514427759644)| false
DouZ, JiangZ, ZhongJ. Efficacy and safety of pregabalin in patients with neuropathic cancer pain undergoing morphine therapy. Asia Pac J Clin Oncol2017;13:e57–e64.
DouZ, JiangZ, ZhongJ. Efficacy and safety of pregabalin in patients with neuropathic cancer pain undergoing morphine therapy. Asia Pac J Clin Oncol 2017;13:e57–e64.10.1111/ajco.12311)| false
Bar AdV, WeinsteinG, DuttaPR, et al.. Gabapentin for the treatment of pain syndrome related to radiation-induced mucositis in patients with head and neck cancer treated with concurrent chemoradiotherapy. Cancer2010;116:4206–4213.
Bar AdV, WeinsteinG, DuttaPR, . Gabapentin for the treatment of pain syndrome related to radiation-induced mucositis in patients with head and neck cancer treated with concurrent chemoradiotherapy. Cancer 2010;116:4206–4213.10.1002/cncr.25274)| false
RaptisE, VadaloucaA, StavropoulouE, et al.. Pregabalin vs. opioids for the treatment of neuropathic cancer pain: a prospective, head-to-head, randomized, open-label study. Pain Pract2014;14:32–42.
RaptisE, VadaloucaA, StavropoulouE, . Pregabalin vs. opioids for the treatment of neuropathic cancer pain: a prospective, head-to-head, randomized, open-label study. Pain Pract 2014;14:32–42.2346481310.1111/papr.12045)| false
DonovanKA, ChangYD, Oberoi-JassalR, et al.. Relationship of cannabis use to patient-reported symptoms in cancer patients seeking supportive/palliative care [published online February 22, 2019]. J Palliat Med. doi: 10.1089/jpm.2018.0533
DonovanKA, ChangYD, Oberoi-JassalR, . Relationship of cannabis use to patient-reported symptoms in cancer patients seeking supportive/palliative care [published online February 22, 2019]. J Palliat Med. doi: 10.1089/jpm.2018.0533)| false
SteeleG, ArnesonT, ZyllaD. A comprehensive review of cannabis in patients with cancer: availability in the USA, general efficacy, and safety. Curr Oncol Rep2019;21:10.
SteeleG, ArnesonT, ZyllaD. A comprehensive review of cannabis in patients with cancer: availability in the USA, general efficacy, and safety. Curr Oncol Rep 2019;21:10.3070731910.1007/s11912-019-0757-7)| false
National Center for Complementary and Integrative Health. Marijuana and Cannabinoids. 2019. Available at: https://nccih.nih.gov/health/marijuana. Accessed April 25, 2019.
PergamSA, WoodfieldMC, LeeCM, et al.. Cannabis use among patients at a comprehensive cancer center in a state with legalized medicinal and recreational use. Cancer2017;123:4488–4497.
PergamSA, WoodfieldMC, LeeCM, . Cannabis use among patients at a comprehensive cancer center in a state with legalized medicinal and recreational use. Cancer 2017;123:4488–4497.10.1002/cncr.30879)| false
TringaleKR, Huynh-LeMP, SalansM, et al.. The role of cancer in marijuana and prescription opioid use in the United States: A population-based analysis from 2005 to 2014. Cancer2019;125:2242–2251.
TringaleKR, Huynh-LeMP, SalansM, . The role of cancer in marijuana and prescription opioid use in the United States: A population-based analysis from 2005 to 2014. Cancer 2019;125:2242–2251.)| false
JohnsonJR, Burnell-NugentM, LossignolD, et al.. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage2010;39:167–179.
JohnsonJR, Burnell-NugentM, LossignolD, . Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage 2010;39:167–179.10.1016/j.jpainsymman.2009.06.00819896326)| false
PortenoyRK, Ganae-MotanED, AllendeS, et al.. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain2012;13:438–449.
LynchME, Cesar-RittenbergP, HohmannAG. A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. J Pain Symptom Manage2014;47:166–173.
LynchME, Cesar-RittenbergP, HohmannAG. A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. J Pain Symptom Manage 2014;47:166–173.2374273710.1016/j.jpainsymman.2013.02.018)| false
MonteAA, SheltonSK, MillsE, et al.. Acute illness associated with cannabis use, by route of exposure: an observational study. Ann Intern Med2019;170:531–537.
MonteAA, SheltonSK, MillsE, . Acute illness associated with cannabis use, by route of exposure: an observational study. Ann Intern Med 2019;170:531–537.10.7326/M18-2809)| false
BandieriE, RomeroM, RipamontiCI, et al..Early Strong Opioid Treatment Study (ESOT) Investigators. Randomized trial of low-dose morphine versus weak opioids in moderate cancer pain. J Clin Oncol2016;34:436–442.
AndersenG, JensenNH, ChristrupL, et al.. Pain, sedation and morphine metabolism in cancer patients during long-term treatment with sustained-release morphine. Palliat Med2002;16:107–114.
AndersenG, JensenNH, ChristrupL, . Pain, sedation and morphine metabolism in cancer patients during long-term treatment with sustained-release morphine. Palliat Med 2002;16:107–114.1196914110.1191/0269216302pm512oa)| false
SandeTA, LairdBJ, FallonMT. The use of opioids in cancer patients with renal impairment-a systematic review. Support Care Cancer 2017;25:661–675.10.1007/s00520-016-3447-027744535)| false
KlepstadP, KaasaS, BorchgrevinkPC. Start of oral morphine to cancer patients: effective serum morphine concentrations and contribution from morphine-6-glucuronide to the analgesia produced by morphine. Eur J Clin Pharmacol2000;55:713–719.
KlepstadP, KaasaS, BorchgrevinkPC. Start of oral morphine to cancer patients: effective serum morphine concentrations and contribution from morphine-6-glucuronide to the analgesia produced by morphine. Eur J Clin Pharmacol 2000;55:713–719.1066344810.1007/s002280050003)| false
KlepstadP, KaasaS, SkaugeM, et al.. Pain intensity and side effects during titration of morphine to cancer patients using a fixed schedule dose escalation. Acta Anaesthesiol Scand2000;44:656–664.
KlepstadP, KaasaS, SkaugeM, . Pain intensity and side effects during titration of morphine to cancer patients using a fixed schedule dose escalation. Acta Anaesthesiol Scand 2000;44:656–664.10.1034/j.1399-6576.2000.440605.x10903012)| false
TiseoPJ, ThalerHT, LapinJ, et al.. Morphine-6-glucuronide concentrations and opioid-related side effects: a survey in cancer patients. Pain1995;61:47–54.
TiseoPJ, ThalerHT, LapinJ, . Morphine-6-glucuronide concentrations and opioid-related side effects: a survey in cancer patients. Pain 1995;61:47–54.764424810.1016/0304-3959(94)00148-8)| false
PortenoyRK, FoleyKM, StulmanJ, et al.. Plasma morphine and morphine-6-glucuronide during chronic morphine therapy for cancer pain: plasma profiles, steady-state concentrations and the consequences of renal failure. Pain1991;47:13–19.
PortenoyRK, FoleyKM, StulmanJ, . Plasma morphine and morphine-6-glucuronide during chronic morphine therapy for cancer pain: plasma profiles, steady-state concentrations and the consequences of renal failure. Pain 1991;47:13–19.177108810.1016/0304-3959(91)90005-I)| false
MercadanteS, VellucciR, CuomoA, et al.. Long-term efficacy and tolerability of intranasal fentanyl in the treatment of breakthrough cancer pain. Support Care Cancer2015;23:1349–1354.
MercadanteS, VellucciR, CuomoA, . Long-term efficacy and tolerability of intranasal fentanyl in the treatment of breakthrough cancer pain. Support Care Cancer 2015;23:1349–1354.10.1007/s00520-014-2491-x25351457)| false
CaraceniA, HanksG, KaasaS, et al..European Association for Palliative Care (EAPC). Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol2012;13:e58–e68.
CaraceniA, HanksG, KaasaS, .European Association for Palliative Care (EAPC). Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 2012;13:e58–e68.)| false
WangDD, MaTT, ZhuHD, et al.. Transdermal fentanyl for cancer pain: trial sequential analysis of 3406 patients from 35 randomized controlled trials. J Cancer Res Ther2018; 14(8, Supplement)14–21.
WangDD, MaTT, ZhuHD, . Transdermal fentanyl for cancer pain: trial sequential analysis of 3406 patients from 35 randomized controlled trials. J Cancer Res Ther 2018; 14(8, Supplement)14–21.10.4103/0973-1482.171368)| false
KornickCA, Santiago-PalmaJ, KhojainovaN, et al.. A safe and effective method for converting cancer patients from intravenous to transdermal fentanyl. Cancer2001;92:3056–3061.
KornickCA, Santiago-PalmaJ, KhojainovaN, . A safe and effective method for converting cancer patients from intravenous to transdermal fentanyl. Cancer 2001;92:3056–3061.10.1002/1097-0142(20011215)92:12<3056::AID-CNCR10166>3.0.CO;2-H11753984)| false
PortenoyRK, TaylorD, MessinaJ, et al.. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain2006;22:805–811.
PortenoyRK, TaylorD, MessinaJ, . A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain 2006;22:805–811.1705756310.1097/01.ajp.0000210932.27945.4a)| false
WeinsteinSM, MessinaJ, XieF. Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic cancer pain: A long-term, open-label safety study. Cancer2009;115:2571–2579.
WeinsteinSM, MessinaJ, XieF. Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic cancer pain: A long-term, open-label safety study. Cancer 2009;115:2571–2579.10.1002/cncr.2427919373888)| false
KirchheinerJ, SchmidtH, TzvetkovM, et al.. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J2007;7:257–265.
KirchheinerJ, SchmidtH, TzvetkovM, . Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J 2007;7:257–265.10.1038/sj.tpj.650040616819548)| false
WrightAW, MatherLE, SmithMT. Hydromorphone-3-glucuronide: a more potent neuro-excitant than its structural analogue, morphine-3-glucuronide. Life Sci2001;69:409–420.
WrightAW, MatherLE, SmithMT. Hydromorphone-3-glucuronide: a more potent neuro-excitant than its structural analogue, morphine-3-glucuronide. Life Sci 2001;69:409–420.10.1016/S0024-3205(01)01133-X11459432)| false
HanHS, LeeKH, LeeKH, et al.. A prospective, open-label, multicenter study of the clinical efficacy of extended-release hydromorphone in treating cancer pain inadequately controlled by other analgesics. Support Care Cancer2014;22:741–750.
HanHS, LeeKH, LeeKH, . A prospective, open-label, multicenter study of the clinical efficacy of extended-release hydromorphone in treating cancer pain inadequately controlled by other analgesics. Support Care Cancer 2014;22:741–750.10.1007/s00520-013-2030-124203087)| false
YuS, ShenW, YuL, et al.. Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. J Pain2014;15:835–844.
YuS, ShenW, YuL, . Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. J Pain 2014;15:835–844.10.1016/j.jpain.2014.04.00824846822)| false
InoueS, SaitoY, TsunetoS, et al.. A randomized, double-blind, non-inferiority study of hydromorphone hydrochloride immediate-release tablets versus oxycodone hydrochloride immediate-release powder for cancer pain: efficacy and safety in Japanese cancer patients. Jpn J Clin Oncol2018;48:542–547.
InoueS, SaitoY, TsunetoS, . A randomized, double-blind, non-inferiority study of hydromorphone hydrochloride immediate-release tablets versus oxycodone hydrochloride immediate-release powder for cancer pain: efficacy and safety in Japanese cancer patients. Jpn J Clin Oncol 2018;48:542–547.10.1093/jjco/hyy03829659913)| false
DavisMP, VargaJ, DickersonD, et al.. Normal-release and controlled-release oxycodone: pharmacokinetics, pharmacodynamics, and controversy. Support Care Cancer2003;11:84–92.
DavisMP, VargaJ, DickersonD, . Normal-release and controlled-release oxycodone: pharmacokinetics, pharmacodynamics, and controversy. Support Care Cancer 2003;11:84–92.12560936)| false
GabrailNY, DvergstenC, AhdiehH. Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: a randomized controlled study. Curr Med Res Opin2004;20:911–918.
GabrailNY, DvergstenC, AhdiehH. Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: a randomized controlled study. Curr Med Res Opin 2004;20:911–918.10.1185/03007990412500385415200750)| false
Schmidt-HansenM, BennettMI, ArnoldS, et al.. Efficacy, tolerability and acceptability of oxycodone for cancer-related pain in adults: an updated Cochrane systematic review. BMJ Support Palliat Care2018;8:117–128.
Schmidt-HansenM, BennettMI, ArnoldS, . Efficacy, tolerability and acceptability of oxycodone for cancer-related pain in adults: an updated Cochrane systematic review. BMJ Support Palliat Care 2018;8:117–128.2933195310.1136/bmjspcare-2017-001457)| false
AhmedzaiSH, NauckF, Bar-SelaG, et al.. A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliat Med2012;26:50–60.
AhmedzaiSH, NauckF, Bar-SelaG, . A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliat Med 2012;26:50–60.10.1177/026921631141886921937568)| false
AhmedzaiSH, LeppertW, JaneckiM, et al.. Long-term safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate-to-severe chronic cancer pain. Support Care Cancer2015;23:823–830.
AhmedzaiSH, LeppertW, JaneckiM, . Long-term safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate-to-severe chronic cancer pain. Support Care Cancer 2015;23:823–830.10.1007/s00520-014-2435-525218610)| false
DavisMP, HomsiJ. The importance of cytochrome P450 monooxygenase CYP2D6 in palliative medicine. Support Care Cancer 2001;9:442–451.10.1007/s00520000022211585271)| false
McPhersonML, WalkerKA, DavisMP, et al.. Safe and appropriate use of methadone in hospice and palliative care: expert consensus white paper. J Pain Symptom Manage2019;57:635–645.
McPhersonML, WalkerKA, DavisMP, . Safe and appropriate use of methadone in hospice and palliative care: expert consensus white paper. J Pain Symptom Manage 2019;57:635–645.3057893410.1016/j.jpainsymman.2018.12.001)| false
ParsonsHA, de la CruzM, El OstaB, et al.. Methadone initiation and rotation in the outpatient setting for patients with cancer pain. Cancer2010;116:520–528.
ParsonsHA, de la CruzM, El OstaB, . Methadone initiation and rotation in the outpatient setting for patients with cancer pain. Cancer 2010;116:520–528.1992478810.1002/cncr.24754)| false
CourtemancheF, DaoD, GagnéF, . Methadone as a coanalgesic for palliative care cancer patients. J Palliat Med 2016;19:972–978.2739983910.1089/jpm.2015.0525)| false
FürstP, LundströmS, KlepstadP, et al.. Improved pain control in terminally ill cancer patients by introducing low-dose oral methadone in addition to ongoing opioid treatment. J Palliat Med2018;21:177–181.
FürstP, LundströmS, KlepstadP, . Improved pain control in terminally ill cancer patients by introducing low-dose oral methadone in addition to ongoing opioid treatment. J Palliat Med 2018;21:177–181.10.1089/jpm.2017.015728792784)| false
KrantzMJ, LewkowiezL, HaysH, . Torsade de pointes associated with very-high-dose methadone. Ann Intern Med 2002;137:501–504.1223035110.7326/0003-4819-137-6-200209170-00010)| false
KrantzMJ, KutinskyIB, RobertsonAD, et al.. Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes. Pharmacotherapy2003;23:802–805.
KrantzMJ, KutinskyIB, RobertsonAD, . Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes. Pharmacotherapy 2003;23:802–805.10.1592/phco.23.6.802.32186)| false
ReddyS, HuiD, El OstaB, et al.. The effect of oral methadone on the QTc interval in advanced cancer patients: a prospective pilot study. J Palliat Med2010;13:33–38.
ReddyS, HuiD, El OstaB, . The effect of oral methadone on the QTc interval in advanced cancer patients: a prospective pilot study. J Palliat Med 2010;13:33–38.10.1089/jpm.2009.018419824814)| false
ChouR, CrucianiRA, FiellinDA, et al..Heart Rhythm Society. Methadone safety: a clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society. J Pain2014;15:321–337.
ChouR, CrucianiRA, FiellinDA, .Heart Rhythm Society. Methadone safety: a clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society. J Pain 2014;15:321–337.2468545810.1016/j.jpain.2014.01.494)| false
AtkinsonTJ, FudinJ, PandulaA, et al.. Medication pain management in the elderly: unique and underutilized analgesic treatment options. Clin Ther2013;35:1669–1689.
RowbothamMC, TwillingL, DaviesPS, . Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med 2003;348:1223–1232.10.1056/NEJMoa02142012660386)| false
GrondS, RadbruchL, MeuserT, et al.. High-dose tramadol in comparison to low-dose morphine for cancer pain relief. J Pain Symptom Manage1999;18:174–179.
RodriguezRF, BravoLE, CastroF, et al.. Incidence of weak opioids adverse events in the management of cancer pain: a double-blind comparative trial. J Palliat Med2007;10:56–60.
RodriguezRF, BravoLE, CastroF, . Incidence of weak opioids adverse events in the management of cancer pain: a double-blind comparative trial. J Palliat Med 2007;10:56–60.1729825410.1089/jpm.2006.0117)| false
WiffenPJ, DerryS, MooreRA. Tramadol with or without paracetamol (acetaminophen) for cancer pain. Cochrane Database Syst Rev 2017;5:CD012508.28510996)| false
AfilaloM, EtropolskiMS, KuperwasserB, et al.. Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study. Clin Drug Investig2010;30:489–505.
AfilaloM, EtropolskiMS, KuperwasserB, . Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study. Clin Drug Investig 2010;30:489–505.20586515)| false
BuynakR, ShapiroDY, OkamotoA, et al.. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled phase III study. Expert Opin Pharmacother2010;11:1787–1804.
BuynakR, ShapiroDY, OkamotoA, . Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled phase III study. Expert Opin Pharmacother 2010;11:1787–1804.10.1517/14656566.2010.49772020578811)| false
SchwartzS, EtropolskiM, ShapiroDY, et al.. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin2011;27:151–162.
SchwartzS, EtropolskiM, ShapiroDY, . Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin 2011;27:151–162.10.1185/03007995.2010.53758921162697)| false
MercadanteS, PorzioG, FerreraP, . Tapentadol in cancer pain management: a prospective open-label study. Curr Med Res Opin 2012;28:1775–1779.10.1185/03007995.2012.73915123057488)| false
MercadanteS, PorzioG, AdileC, et al.. Tapentadol at medium to high doses in patients previously receiving strong opioids for the management of cancer pain. Curr Med Res Opin2014;30:2063–2068.
MercadanteS, PorzioG, AdileC, . Tapentadol at medium to high doses in patients previously receiving strong opioids for the management of cancer pain. Curr Med Res Opin 2014;30:2063–2068.10.1185/03007995.2014.93479324926734)| false
NaingC, AungK, RaclozV, et al.. Safety and efficacy of transdermal buprenorphine for the relief of cancer pain. J Cancer Res Clin Oncol2013;139:1963–1970.
NaingC, AungK, RaclozV, . Safety and efficacy of transdermal buprenorphine for the relief of cancer pain. J Cancer Res Clin Oncol 2013;139:1963–1970.10.1007/s00432-013-1487-023922192)| false
PergolizziJV, Jr., MercadanteS, EchaburuAV, et al..Euromed Communications meeting. The role of transdermal buprenorphine in the treatment of cancer pain: an expert panel consensus. Curr Med Res Opin2009;25:1517–1528.
PergolizziJV, Jr., MercadanteS, EchaburuAV, .Euromed Communications meeting. The role of transdermal buprenorphine in the treatment of cancer pain: an expert panel consensus. Curr Med Res Opin 2009;25:1517–1528.10.1185/03007990902920731)| false
DeandreaS, CorliO, MoschettiI, et al.. Managing severe cancer pain: the role of transdermal buprenorphine: a systematic review. Ther Clin Risk Manag2009;5:707–718.
DeandreaS, CorliO, MoschettiI, . Managing severe cancer pain: the role of transdermal buprenorphine: a systematic review. Ther Clin Risk Manag 2009;5:707–718.19774212)| false
MelilliG, Samolsky DekelBG, FrenquelliC, et al.. Transdermal opioids for cancer pain control in patients with renal impairment. J Opioid Manag2014;10:85–93.
MelilliG, Samolsky DekelBG, FrenquelliC, . Transdermal opioids for cancer pain control in patients with renal impairment. J Opioid Manag 2014;10:85–93.10.5055/jom.2014.019724715663)| false
LundorffL, SjøgrenP, HansenOB, et al.. Switching from high doses of pure μ-opioid agonists to transdermal buprenorphine in patients with cancer: a feasibility study. J Opioid Manag2013;9:255–262.
LundorffL, SjøgrenP, HansenOB, . Switching from high doses of pure μ-opioid agonists to transdermal buprenorphine in patients with cancer: a feasibility study. J Opioid Manag 2013;9:255–262.10.5055/jom.2013.0166)| false
HardyJ, QuinnS, FazekasB, et al.. Randomized, double-blind, placebo-controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. J Clin Oncol2012;30:3611–3617.
HardyJ, QuinnS, FazekasB, . Randomized, double-blind, placebo-controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. J Clin Oncol 2012;30:3611–3617.2296596010.1200/JCO.2012.42.1081)| false
BredlauAL, ThakurR, KoronesDN, et al.. Ketamine for pain in adults and children with cancer: a systematic review and synthesis of the literature. Pain Med2013;14:1505–1517.
BredlauAL, ThakurR, KoronesDN, . Ketamine for pain in adults and children with cancer: a systematic review and synthesis of the literature. Pain Med 2013;14:1505–1517.10.1111/pme.12182)| false
DeWildeKE, LevitchCF, MurroughJW, et al.. The promise of ketamine for treatment-resistant depression: current evidence and future directions. Ann N Y Acad Sci2015;1345:47–58.
DeWildeKE, LevitchCF, MurroughJW, . The promise of ketamine for treatment-resistant depression: current evidence and future directions. Ann N Y Acad Sci 2015;1345:47–58.10.1111/nyas.1264625649308)| false
FondG, LoundouA, RabuC, et al.. Ketamine administration in depressive disorders: a systematic review and meta-analysis. Psychopharmacology (Berl)2014;231:3663–3676.
LeeEE, Della SelvaMP, LiuA, et al.. Ketamine as a novel treatment for major depressive disorder and bipolar depression: a systematic review and quantitative meta-analysis. Gen Hosp Psychiatry2015;37:178–184.
LeeEE, Della SelvaMP, LiuA, . Ketamine as a novel treatment for major depressive disorder and bipolar depression: a systematic review and quantitative meta-analysis. Gen Hosp Psychiatry 2015;37:178–184.2569822810.1016/j.genhosppsych.2015.01.003)| false
SharmaS, RajagopalMR, PalatG, et al.. A phase II pilot study to evaluate use of intravenous lidocaine for opioid-refractory pain in cancer patients. J Pain Symptom Manage2009;37:85–93.
SharmaS, RajagopalMR, PalatG, . A phase II pilot study to evaluate use of intravenous lidocaine for opioid-refractory pain in cancer patients. J Pain Symptom Manage 2009;37:85–93.10.1016/j.jpainsymman.2007.12.02318599258)| false
JendoubiA, NaceurIB, BouzouitaA, et al.. A comparison between intravenous lidocaine and ketamine on acute and chronic pain after open nephrectomy: A prospective, double-blind, randomized, placebo-controlled study. Saudi J Anaesth2017;11:177–184.
JendoubiA, NaceurIB, BouzouitaA, . A comparison between intravenous lidocaine and ketamine on acute and chronic pain after open nephrectomy: A prospective, double-blind, randomized, placebo-controlled study. Saudi J Anaesth 2017;11:177–184.2844295610.4103/1658-354X.203027)| false
StevensRA, GhaziSM. Routes of opioid analgesic therapy in the management of cancer pain. Cancer Contr 2000;7:132–141.10.1177/107327480000700203)| false
HarrisJT, Suresh KumarK, RajagopalMR. Intravenous morphine for rapid control of severe cancer pain. Palliat Med 2003;17:248–256.1272547810.1191/0269216303pm695oa)| false
NijlandL, SchmidtP, FroschM, et al.. Subcutaneous or intravenous opioid administration by patient-controlled analgesia in cancer pain: a systematic literature review. Support Care Cancer2019;27:33–42.
NijlandL, SchmidtP, FroschM, . Subcutaneous or intravenous opioid administration by patient-controlled analgesia in cancer pain: a systematic literature review. Support Care Cancer 2019;27:33–42.10.1007/s00520-018-4368-x30056529)| false
DaviesA, BuchananA, ZeppetellaG, et al.. Breakthrough cancer pain: an observational study of 1000 European oncology patients. J Pain Symptom Manage2013;46:619–628.
DaviesA, BuchananA, ZeppetellaG, . Breakthrough cancer pain: an observational study of 1000 European oncology patients. J Pain Symptom Manage 2013;46:619–628.2352336110.1016/j.jpainsymman.2012.12.009)| false
JandhyalaR, FullartonJR, BennettMI. Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials. J Pain Symptom Manage2013;46:573–580.
ZeppetellaG, DaviesA, EijgelshovenI, JansenJP. A network meta-analysis of the efficacy of opioid analgesics for the management of breakthrough cancer pain episodes. J Pain Symptom Manage2014;47:772–785.
ZeppetellaG, DaviesA, EijgelshovenI, JansenJP. A network meta-analysis of the efficacy of opioid analgesics for the management of breakthrough cancer pain episodes. J Pain Symptom Manage 2014;47:772–785.10.1016/j.jpainsymman.2013.05.02023981487)| false
ButlerSF, BudmanSH, FernandezKC, . Development and validation of the Current Opioid Misuse Measure. Pain 2007;130:144–156.10.1016/j.pain.2007.01.01417493754)| false
MeltzerEC, RybinD, SaitzR, et al.. Identifying prescription opioid use disorder in primary care: diagnostic characteristics of the Current Opioid Misuse Measure (COMM). Pain2011;152:397–402.
MeltzerEC, RybinD, SaitzR, . Identifying prescription opioid use disorder in primary care: diagnostic characteristics of the Current Opioid Misuse Measure (COMM). Pain 2011;152:397–402.2117703510.1016/j.pain.2010.11.006)| false
AnghelescuDL, EhrentrautJH, FaughnanLG. Opioid misuse and abuse: risk assessment and management in patients with cancer pain. J Natl Compr Canc Netw2013;11:1023–1031.
AnghelescuDL, EhrentrautJH, FaughnanLG. Opioid misuse and abuse: risk assessment and management in patients with cancer pain. J Natl Compr Canc Netw 2013;11:1023–1031.2394617810.6004/jnccn.2013.0120)| false
McNicolE, Horowicz-MehlerN, FiskRA, et al..Americal Pain Society. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. J Pain2003;4:231–256.
McNicolE, Horowicz-MehlerN, FiskRA, .Americal Pain Society. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. J Pain 2003;4:231–256.10.1016/S1526-5900(03)00556-X)| false
MercadanteS. Pathophysiology and treatment of opioid-related myoclonus in cancer patients. Pain 1998;74:5–9.951455410.1016/S0304-3959(97)00090-0)| false
MorylN, CarverA, FoleyKM. Pain and palliation. In: Holland JF, Frei E, eds. Cancer Medicine. Vol. I7th ed. Hamilton, ON: BC Decker Inc; 2006:1113-1124.
154.
MorylN, ObbensEA, OzigboOH, et al.. Analgesic effect of gefitinib in the treatment of non-small cell lung cancer. J Support Oncol2006;4:111.
MorylN, ObbensEA, OzigboOH, . Analgesic effect of gefitinib in the treatment of non-small cell lung cancer. J Support Oncol 2006;4:111.16553135)| false
RajagopalA, Vassilopoulou-SellinR, PalmerJL, et al.. Symptomatic hypogonadism in male survivors of cancer with chronic exposure to opioids. Cancer2004;100:851–858.
RajagopalA, Vassilopoulou-SellinR, PalmerJL, . Symptomatic hypogonadism in male survivors of cancer with chronic exposure to opioids. Cancer 2004;100:851–858.1477044410.1002/cncr.20028)| false
BoettgerS, BreitbartW. Atypical antipsychotics in the management of delirium: a review of the empirical literature. Palliat Support Care2005;3:227–237.
BoettgerS, BreitbartW. Atypical antipsychotics in the management of delirium: a review of the empirical literature. Palliat Support Care 2005;3:227–237.1659446210.1017/S1478951505050352)| false
BreitbartW, MarottaR, PlattMM, et al.. A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry1996;153:231–237.
BreitbartW, MarottaR, PlattMM, . A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry 1996;153:231–237.856120410.1176/ajp.153.2.231)| false
BrueraE, BelzileM, NeumannC, et al.. A double-blind, crossover study of controlled-release metoclopramide and placebo for the chronic nausea and dyspepsia of advanced cancer. J Pain Symptom Manage2000;19:427–435.
BrueraE, BelzileM, NeumannC, . A double-blind, crossover study of controlled-release metoclopramide and placebo for the chronic nausea and dyspepsia of advanced cancer. J Pain Symptom Manage 2000;19:427–435.10.1016/S0885-3924(00)00138-X10908823)| false
MarinellaMA. Acute colonic pseudo-obstruction complicated by cecal perforation in a patient with Parkinson’s disease. South Med J 1997;90:1023–1026.10.1097/00007611-199710000-00009)| false
ReissigJE, RybarczykAM. Pharmacologic treatment of opioid-induced sedation in chronic pain. Ann Pharmacother 2005;39:727–731.1575579510.1345/aph.1E309)| false
TarcatuD, TamasdanC, MorylN, et al.. Are we still scratching the surface? A case of intractable pruritus following systemic opioid analgesia. J Opioid Manag2007;3:167–170.
TarcatuD, TamasdanC, MorylN, . Are we still scratching the surface? A case of intractable pruritus following systemic opioid analgesia. J Opioid Manag 2007;3:167–170.1802754310.5055/jom.2007.0055)| false
HawleyPH, ByeonJJ. A comparison of sennosides-based bowel protocols with and without docusate in hospitalized patients with cancer. J Palliat Med2008;11:575–581.
HawleyPH, ByeonJJ. A comparison of sennosides-based bowel protocols with and without docusate in hospitalized patients with cancer. J Palliat Med 2008;11:575–581.1845461010.1089/jpm.2007.0178)| false
TarumiY, WilsonMP, SzafranO, et al.. Randomized, double-blind, placebo-controlled trial of oral docusate in the management of constipation in hospice patients. J Pain Symptom Manage2013;45:2–13.
TarumiY, WilsonMP, SzafranO, . Randomized, double-blind, placebo-controlled trial of oral docusate in the management of constipation in hospice patients. J Pain Symptom Manage 2013;45:2–13.10.1016/j.jpainsymman.2012.02.00822889861)| false
RauckR, SlatkinNE, StamblerN, et al.. Randomized, double-blind trial of oral methylnaltrexone for the treatment of opioid-induced constipation in patients with chronic noncancer pain. Pain Pract2017;17:820–828.
RauckR, SlatkinNE, StamblerN, . Randomized, double-blind trial of oral methylnaltrexone for the treatment of opioid-induced constipation in patients with chronic noncancer pain. Pain Pract 2017;17:820–828.2786020810.1111/papr.12535)| false
MichnaE, BlonskyER, SchulmanS, et al.. Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: a randomized controlled study. J Pain2011;12:554–562.
MichnaE, BlonskyER, SchulmanS, . Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: a randomized controlled study. J Pain 2011;12:554–562.10.1016/j.jpain.2010.11.008)| false
PortenoyRK, ThomasJ, Moehl BoatwrightML, et al.. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging study. J Pain Symptom Manage2008;35:458–468.
Sanz RubialesA, del Valle RiveroML. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med 2008;359:1070–1071.10.1056/NEJMc081373)| false
ThomasJ, KarverS, CooneyGA, . Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med 2008;358:2332–2343.1850912010.1056/NEJMoa0707377)| false
CheyWD, WebsterL, SostekM, . Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med 2014;370:2387–2396.2489681810.1056/NEJMoa1310246)| false
KatakamiN, HaradaT, MurataT, et al.. Randomized phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. J Clin Oncol2017;35:3859–3866.
KatakamiN, HaradaT, MurataT, . Randomized phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. J Clin Oncol 2017;35:3859–3866.2896817110.1200/JCO.2017.73.0853)| false
NeeJ, ZakariM, SugarmanMA, et al.. Efficacy of treatments for opioid-induced constipation: systematic review and meta-analysis. Clin Gastroenterol Hepatol2018;16:1569–1584.
CryerB, KatzS, VallejoR, et al.. A randomized study of lubiprostone for opioid-induced constipation in patients with chronic noncancer pain. Pain Med2014;15:1825–1834.
CryerB, KatzS, VallejoR, . A randomized study of lubiprostone for opioid-induced constipation in patients with chronic noncancer pain. Pain Med 2014;15:1825–1834.2471683510.1111/pme.12437)| false
JamalMM, AdamsAB, JansenJP, et al.. A randomized, placebo-controlled trial of lubiprostone for opioid-induced constipation in chronic noncancer pain. Am J Gastroenterol2015;110:725–732.
JamalMM, AdamsAB, JansenJP, . A randomized, placebo-controlled trial of lubiprostone for opioid-induced constipation in chronic noncancer pain. Am J Gastroenterol 2015;110:725–732.2591622010.1038/ajg.2015.106)| false
ChangL, LemboAJ, LavinsBJ, et al.. The impact of abdominal pain on global measures in patients with chronic idiopathic constipation, before and after treatment with linaclotide: a pooled analysis of two randomised, double-blind, placebo-controlled, phase 3 trials. Aliment Pharmacol Ther2014;40:1302–1312.
ChangL, LemboAJ, LavinsBJ, . The impact of abdominal pain on global measures in patients with chronic idiopathic constipation, before and after treatment with linaclotide: a pooled analysis of two randomised, double-blind, placebo-controlled, phase 3 trials. Aliment Pharmacol Ther 2014;40:1302–1312.10.1111/apt.1298525312449)| false
KaneishiK, KawabataM, MoritaT. Olanzapine for the relief of nausea in patients with advanced cancer and incomplete bowel obstruction. J Pain Symptom Manage2012;44:604–607.
KaneishiK, KawabataM, MoritaT. Olanzapine for the relief of nausea in patients with advanced cancer and incomplete bowel obstruction. J Pain Symptom Manage 2012;44:604–607.10.1016/j.jpainsymman.2011.10.02322771132)| false
NavariRM, NagyCK, GraySE. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer2013;21:1655–1663.
NavariRM, NagyCK, GraySE. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer 2013;21:1655–1663.2331460310.1007/s00520-012-1710-6)| false
BrueraE, SeifertL, WatanabeS, et al.. Chronic nausea in advanced cancer patients: a retrospective assessment of a metoclopramide-based antiemetic regimen. J Pain Symptom Manage1996;11:147–153.
BrueraE, SeifertL, WatanabeS, . Chronic nausea in advanced cancer patients: a retrospective assessment of a metoclopramide-based antiemetic regimen. J Pain Symptom Manage 1996;11:147–153.10.1016/0885-3924(95)00161-18851371)| false
HermanTS, EinhornLH, JonesSE, et al.. Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N Engl J Med1979;300:1295–1297.
HermanTS, EinhornLH, JonesSE, . Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N Engl J Med 1979;300:1295–1297.10.1056/NEJM197906073002302375088)| false
SteeleN, GrallaRJ, BraunDWJr, et al.. Double-blind comparison of the antiemetic effects of nabilone and prochlorperazine on chemotherapy-induced emesis. Cancer Treat Rep1980;64:219–224.
SteeleN, GrallaRJ, BraunDWJr, . Double-blind comparison of the antiemetic effects of nabilone and prochlorperazine on chemotherapy-induced emesis. Cancer Treat Rep 1980;64:219–224.6250699)| false
SallanSE, CroninC, ZelenM, et al.. Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine. N Engl J Med1980;302:135–138.
SallanSE, CroninC, ZelenM, . Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine. N Engl J Med 1980;302:135–138.10.1056/NEJM198001173020302)| false
SallanSE, ZinbergNE, FreiEIII. Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. N Engl J Med1975;293:795–797.
SallanSE, ZinbergNE, FreiEIII. Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. N Engl J Med 1975;293:795–797.109944910.1056/NEJM197510162931603)| false
ChamberlainJM, KleinBL. A comprehensive review of naloxone for the emergency physician. Am J Emerg Med 1994;12:650–660.10.1016/0735-6757(94)90033-77945608)| false
GagnonP, AllardP, MâsseB, et al.. Delirium in terminal cancer: a prospective study using daily screening, early diagnosis, and continuous monitoring. J Pain Symptom Manage2000;19:412–426.
GagnonP, AllardP, MâsseB, . Delirium in terminal cancer: a prospective study using daily screening, early diagnosis, and continuous monitoring. J Pain Symptom Manage 2000;19:412–426.10.1016/S0885-3924(00)00143-3)| false
AgarMR, LawlorPG, QuinnS, et al.. Efficacy of oral risperidone, haloperidol, or placebo for symptoms of delirium among patients in palliative care: a randomized clinical trial. JAMA Intern Med2017;177:34–42.
AgarMR, LawlorPG, QuinnS, . Efficacy of oral risperidone, haloperidol, or placebo for symptoms of delirium among patients in palliative care: a randomized clinical trial. JAMA Intern Med 2017;177:34–42.2791877810.1001/jamainternmed.2016.7491)| false
HirstJM, VaughanCL, IrwinSA. Delirium: use antipsychotics when appropriate and appropriately. J Palliat Med 2017;20:799.10.1089/jpm.2017.014528410450)| false
HuiD, Frisbee-HumeS, WilsonA, et al.. Effect of lorazepam with haloperidol vs haloperidol alone on agitated delirium in patients with advanced cancer receiving palliative care: a randomized clinical trial. JAMA2017;318:1047–1056.
HuiD, Frisbee-HumeS, WilsonA, . Effect of lorazepam with haloperidol vs haloperidol alone on agitated delirium in patients with advanced cancer receiving palliative care: a randomized clinical trial. JAMA 2017;318:1047–1056.2897530710.1001/jama.2017.11468)| false
BrueraE, MacmillanK, HansonJ, et al.. The cognitive effects of the administration of narcotic analgesics in patients with cancer pain. Pain1989;39:13–16.
BrueraE, MacmillanK, HansonJ, . The cognitive effects of the administration of narcotic analgesics in patients with cancer pain. Pain 1989;39:13–16.10.1016/0304-3959(89)90169-32812850)| false
U.S. Food and Drug Administration. FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. 2016. Available at: https://www.fda.gov/downloads/drugs/drugsafety/ucm518672.pdf. Accessed March 7, 2019.
CoffinPO, BeharE, RoweC, et al.. Nonrandomized intervention study of naloxone coprescription for primary care patients receiving long-term opioid therapy for pain. Ann Intern Med2016;165:245–252.
CoffinPO, BeharE, RoweC, . Nonrandomized intervention study of naloxone coprescription for primary care patients receiving long-term opioid therapy for pain. Ann Intern Med 2016;165:245–252.2736698710.7326/M15-2771)| false
SlatkinNE. Opioid switching and rotation in primary care: implementation and clinical utility. Curr Med Res Opin 2009;25:2133–2150.1960170310.1185/03007990903120158)| false
VissersKC, BesseK, HansG, . Opioid rotation in the management of chronic pain: where is the evidence?Pain Pract 2010;10:85–93.2007055210.1111/j.1533-2500.2009.00335.x)| false
ReddyA, YennurajalingamS, DesaiH, . The opioid rotation ratio of hydrocodone to strong opioids in cancer patients. Oncologist 2014;19:1186–1193.2534231610.1634/theoncologist.2014-0130)| false
ReddyA, TayjasanantS, HaiderA, . The opioid rotation ratio of strong opioids to transdermal fentanyl in cancer patients. Cancer 2016;122:149–156.10.1002/cncr.2968826451687)| false
ReddyA, YennurajalingamS, ReddyS, et al.. The opioid rotation ratio from transdermal fentanyl to “strong” opioids in patients with cancer pain. J Pain Symptom Manage2016;51:1040–1045.
ReddyA, YennurajalingamS, ReddyS, . The opioid rotation ratio from transdermal fentanyl to “strong” opioids in patients with cancer pain. J Pain Symptom Manage 2016;51:1040–1045.2682667510.1016/j.jpainsymman.2015.12.312)| false
McLeanS, TwomeyF. Methods of rotation from another strong opioid to methadone for the management of cancer pain: a systematic review of the available evidence. J Pain Symptom Manage2015;50:248–259.
McLeanS, TwomeyF. Methods of rotation from another strong opioid to methadone for the management of cancer pain: a systematic review of the available evidence. J Pain Symptom Manage 2015;50:248–259.10.1016/j.jpainsymman.2015.02.02925896106)| false
DartRC, SurrattHL, CiceroTJ, . Trends in opioid analgesic abuse and mortality in the United States. N Engl J Med 2015;372:241–248.10.1056/NEJMsa140614325587948)| false
FDA takes important steps to encourage appropriate and rational prescribing of opioids through final approval of new safety measures governing the use of immediate-release opioid analgesic medications; 2018. Available at: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm620935.htm.
BarclayJS, OwensJE, BlackhallLJ. Screening for substance abuse risk in cancer patients using the Opioid Risk Tool and urine drug screen. Support Care Cancer2014;22:1883–1888.
BarclayJS, OwensJE, BlackhallLJ. Screening for substance abuse risk in cancer patients using the Opioid Risk Tool and urine drug screen. Support Care Cancer 2014;22:1883–1888.10.1007/s00520-014-2167-624563103)| false
FinnerupNB, SindrupSH, JensenTS. The evidence for pharmacological treatment of neuropathic pain. Pain 2010;150:573–581.10.1016/j.pain.2010.06.01920705215)| false
CaraceniA, ZeccaE, BonezziC, et al.. Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group. J Clin Oncol2004;22:2909–2917.
CaraceniA, ZeccaE, BonezziC, . Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group. J Clin Oncol 2004;22:2909–2917.10.1200/JCO.2004.08.141)| false
BennettMI. Effectiveness of antiepileptic or antidepressant drugs when added to opioids for cancer pain: systematic review. Palliat Med2011;25:553–559.
BennettMI. Effectiveness of antiepileptic or antidepressant drugs when added to opioids for cancer pain: systematic review. Palliat Med 2011;25:553–559.10.1177/026921631037854620671006)| false
KaneCM, MulveyMR, WrightS, et al.. Opioids combined with antidepressants or antiepileptic drugs for cancer pain: Systematic review and meta-analysis. Palliat Med2018;32:276–286.
KaneCM, MulveyMR, WrightS, . Opioids combined with antidepressants or antiepileptic drugs for cancer pain: Systematic review and meta-analysis. Palliat Med 2018;32:276–286.10.1177/026921631771182628604172)| false
FlemingJA, O’ConnorBD. Use of lidocaine patches for neuropathic pain in a comprehensive cancer centre. Pain Res Manag 2009;14:381–388.10.1155/2009/723179)| false
GammaitoniAR, AlvarezNA, GalerBS. Safety and tolerability of the lidocaine patch 5%, a targeted peripheral analgesic: a review of the literature. J Clin Pharmacol2003;43:111–117.
GammaitoniAR, AlvarezNA, GalerBS. Safety and tolerability of the lidocaine patch 5%, a targeted peripheral analgesic: a review of the literature. J Clin Pharmacol 2003;43:111–117.1261666110.1177/0091270002239817)| false
Garzón-RodríguezC, Casals MerchanM, Calsina-BernaA, et al.. Lidocaine 5 % patches as an effective short-term co-analgesic in cancer pain. Preliminary results. Support Care Cancer2013;21:3153–3158.
Garzón-RodríguezC, Casals MerchanM, Calsina-BernaA, . Lidocaine 5 % patches as an effective short-term co-analgesic in cancer pain. Preliminary results. Support Care Cancer 2013;21:3153–3158.2400004110.1007/s00520-013-1948-7)| false
LiuZ, XuY, LiuZL, et al.. Combined application of diclofenac and celecoxib with an opioid yields superior efficacy in metastatic bone cancer pain: a randomized controlled trial. Int J Clin Oncol2017;22:980–985.
LiuZ, XuY, LiuZL, . Combined application of diclofenac and celecoxib with an opioid yields superior efficacy in metastatic bone cancer pain: a randomized controlled trial. Int J Clin Oncol 2017;22:980–985.10.1007/s10147-017-1133-y)| false
SimaL, FangWX, WuXM, et al.. Efficacy of oxycodone/paracetamol for patients with bone-cancer pain: a multicenter, randomized, double-blinded, placebo-controlled trial. J Clin Pharm Ther2012;37:27–31.
ChowE, MeyerRM, DingK, et al.. Dexamethasone in the prophylaxis of radiation-induced pain flare after palliative radiotherapy for bone metastases: a double-blind, randomised placebo-controlled, phase 3 trial. Lancet Oncol2015;16:1463–1472.
ChowE, MeyerRM, DingK, . Dexamethasone in the prophylaxis of radiation-induced pain flare after palliative radiotherapy for bone metastases: a double-blind, randomised placebo-controlled, phase 3 trial. Lancet Oncol 2015;16:1463–1472.10.1016/S1470-2045(15)00199-026489389)| false
BodyJJ, DielIJ, LichinitzerM, et al.. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer2004;90:1133–1137.
BodyJJ, DielIJ, LichinitzerM, . Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer 2004;90:1133–1137.1502679110.1038/sj.bjc.6601663)| false
BodyJJ, DielIJ, BellR, et al.. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain2004;111:306–312.
BodyJJ, DielIJ, BellR, . Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 2004;111:306–312.10.1016/j.pain.2004.07.01115363874)| false
CleelandCS, BodyJJ, StopeckA, et al.. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid. Cancer2013;119:832–838.
CleelandCS, BodyJJ, StopeckA, . Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid. Cancer 2013;119:832–838.2295181310.1002/cncr.27789)| false
RosenLS, GordonD, KaminskiM, et al.. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J2001;7:377–387.
RosenLS, GordonD, KaminskiM, . Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001;7:377–387.11693896)| false
WardleyA, DavidsonN, Barrett-LeeP, et al.. Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. Br J Cancer2005;92:1869–1876.
WardleyA, DavidsonN, Barrett-LeeP, . Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. Br J Cancer 2005;92:1869–1876.10.1038/sj.bjc.660255115870721)| false
Vadhan-RajS, von MoosR, FallowfieldLJ, et al.. Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acid. Ann Oncol2012;23:3045–3051.
Vadhan-RajS, von MoosR, FallowfieldLJ, . Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acid. Ann Oncol 2012;23:3045–3051.2285140610.1093/annonc/mds175)| false
MartinM, BellR, BourgeoisH, et al.. Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. Clin Cancer Res2012;18:4841–4849.
MartinM, BellR, BourgeoisH, . Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. Clin Cancer Res 2012;18:4841–4849.10.1158/1078-0432.CCR-11-331022893628)| false
Van PoznakC, SomerfieldMR, BarlowWE, et al.. Role of bone-modifying agents in metastatic breast cancer: an American Society of Clinical Oncology–Cancer Care Ontario Focused Guideline Update. J Clin Oncol2017;35:3978–3986.
Van PoznakC, SomerfieldMR, BarlowWE, . Role of bone-modifying agents in metastatic breast cancer: an American Society of Clinical Oncology–Cancer Care Ontario Focused Guideline Update. J Clin Oncol 2017;35:3978–3986.10.1200/JCO.2017.75.4614)| false
MalviyaA, GerrandC. Evidence for orthopaedic surgery in the treatment of metastatic bone disease of the extremities: a review article. Palliat Med2012;26:788–796.
MalviyaA, GerrandC. Evidence for orthopaedic surgery in the treatment of metastatic bone disease of the extremities: a review article. Palliat Med 2012;26:788–796.2193064710.1177/0269216311419882)| false
